Literature DB >> 15897570

The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer.

Michael J Goodheart1, Justine M Ritchie, Stephen L Rose, John P Fruehauf, Barry R De Young, Richard E Buller.   

Abstract

PURPOSE: Multiple angiogenic factors may influence tumor progression and metastasis. Several are modified by the p53 gene. We sought to identify molecular markers for high-risk stage I epithelial ovarian cancers. EXPERIMENTAL
DESIGN: Seventy-seven consecutive stage I epithelial ovarian cancers were evaluated for p53, CD31 microvessel density, thrombospondin-1, vascular endothelial growth factor (VEGF), p21 immunohistochemical staining, and p53 gene mutations. Molecular marker impact upon disease-specific survival, disease recurrence, and distant recurrence was evaluated with Cox regression.
RESULTS: There were 12 deaths from disease. Twelve of the 77 tumors contained p53 mutations-10 missense and 3 null (one tumor had two mutations). Fesddration Internationale des Gynaecologistes et Obstetristes substage (IA/IB versus IC; P < 0.001) and VEGF staining (P = 0.02) were significant in bivariate models with relationship to disease-specific survival. Stage (P = 0.0004), grade (P = 0.008), histology (P = 0.0025), p53 dysfunction (positive stain and/or mutation; P = 0.048), and microvessel density (P = 0.04) were significant in bivariate models with relationship to time to recurrence. In multivariate analyses among stage IC patients, failure to receive chemotherapy and microvessel density were associated with disease-specific survival, time to recurrence, and time to distant recurrence with hazard ratios of 4.8 to 44.1.
CONCLUSIONS: The p53-dependent molecular markers of angiogenesis are of limited utility in developing a clinical strategy for postoperative management of stage I ovarian carcinoma. Microvessel density impacts survival and metastasis for high-risk stage IC disease. Adjuvant chemotherapy is necessary, but not sufficient, for cure of high-risk stage I epithelial ovarian cancers.

Entities:  

Mesh:

Year:  2005        PMID: 15897570     DOI: 10.1158/1078-0432.CCR-04-0056

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

Review 1.  Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.

Authors:  Linjuan Xu; Jing Cai; Qiang Yang; Hui Ding; Liying Wu; Tao Li; Zehua Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-18       Impact factor: 4.553

2.  Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Bradley J Monk; Joan L Walker; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Gini F Fleming; Peter C Lim; Stephen C Rubin; Noriyuki Katsumata; Sharon X Liang
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

3.  Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer in vivo.

Authors:  Wei Li; Mei-Lin Liu; Jia-Hui Cai; Yun-Xian Tang; Ling-Yun Zhai; Jun Zhang
Journal:  Oncol Lett       Date:  2012-04-23       Impact factor: 2.967

4.  ING4 is negatively correlated with microvessel density in colon cancer.

Authors:  Chun Lou; Shixiong Jiang; Xinggang Guo; Xin-shu Dong
Journal:  Tumour Biol       Date:  2012-09-28

5.  Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.

Authors:  Minghai Shao; Stacy Hollar; Daphne Chambliss; Jordan Schmitt; Robert Emerson; Bhadrani Chelladurai; Susan Perkins; Mircea Ivan; Daniela Matei
Journal:  Mol Cancer Ther       Date:  2012-06-13       Impact factor: 6.261

6.  Expression of ING4 is negatively correlated with cellular proliferation and microvessel density in human glioma.

Authors:  Bin Shao; Enzhong Liu
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

7.  Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies.

Authors:  Robert A Burger
Journal:  J Gynecol Oncol       Date:  2010-03-31       Impact factor: 4.401

Review 8.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

Review 9.  Antiangiogenic drugs in ovarian cancer.

Authors:  G C Kumaran; G C Jayson; A R Clamp
Journal:  Br J Cancer       Date:  2008-11-11       Impact factor: 7.640

10.  Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.

Authors:  P de Graeff; A P G Crijns; S de Jong; M Boezen; W J Post; E G E de Vries; A G J van der Zee; G H de Bock
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.